Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Ho-Young Yhim, MD, Won-Il Choi, MD, Sung-Hyun Kim, MD PhD, Seung-Hyun Nam, MD, Kyoung Ha Kim, Yeung-Chul Mun, MD PhD, Hun-Gyu Hwang, MD, Doyeun Oh, MD, Keun-Wook Lee, MD, Eun-Kee Song, MD, Yong Shik Kwon, MD, Soo-Mee Bang, MD PhD

Blood (2017) 130 (Supplement 1): 3711.

https://doi.org/10.1182/blood.V130.Suppl_1.3711.3711

Published: 2017

Journal Articles

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2864.

https://doi.org/10.1182/blood.V130.Suppl_1.2864.2864

Published: 2017

Journal Articles

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Sung-Eun Lee, MD, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, MD PhD, Young-Woong Won, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2873.

https://doi.org/10.1182/blood.V130.Suppl_1.2873.2873

Published: 2017

Journal Articles

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Blood (2017) 130 (Supplement 1): 3130.

https://doi.org/10.1182/blood.V130.Suppl_1.3130.3130

Published: 2017

Journal Articles

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Kyoung Ha Kim, Ho-Young Yhim, MD, Won-Il Choi, Sung-Hyun Kim, MD PhD, Yeung-Chul Mun, MD PhD, Soo-Mee Bang, MD PhD, Doyeun Oh, MD, Ji Hyun Lee, MD PhD, Ji Yun Lee, MD

Blood (2017) 130 (Supplement 1): 4914.

https://doi.org/10.1182/blood.V130.Suppl_1.4914.4914

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Won-Sik Lee, MD PhD, Hye-Young Song, Hyeoung-Joon Kim, Jee Hyun Kong, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Yunsuk Choi, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 1593.

https://doi.org/10.1182/blood.V130.Suppl_1.1593.1593

Published: 2017

Journal Articles

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Blood (2017) 130 (Supplement 1): 4257.

https://doi.org/10.1182/blood.V130.Suppl_1.4257.4257

Published: 2017

Journal Articles

Predictors of General Discomfort, Limitations in Activities of Daily Living, and Intention of a Second Donation in Unrelated Hematopoietic Stem Cell Donation

Mark Lee, Jin Ho Jang, Hyo Jin Min, PhD, Hyung In Jang, Jung Hwa Nah, Chuhl Joo Lyu, MD PhD, Kyou Sup Han, MD PhD, Jong-Ho Won, MD, Young Ho Lee, MD PhD, So Young Chong, MD, Yeung Chul Mun, MD PhD, Won Sik Lee, MD PhD, Seok Jin Kim, Inho Kim, MD PhD

Blood (2016) 128 (22): 3375.

https://doi.org/10.1182/blood.V128.22.3375.3375

Published: 2016

Journal Articles

VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma

Min Kyoung Kim, Cheolwon Suh, MD, Hyun Sook Chi, Hee Soon Cho, Kyung Hee Lee, Gyeong-Won Lee, In-Suk Kim, MD, PhD, Hyeon Seok Eom, Sun-Young Kong, MD, PhD, Sung Hwa Bae, Hun-Mo Ryoo, MD, PhD, Yeung-Chul Mun, MD, PhD, Hwasoon Chung, Myung Soo Hyun

Blood (2010) 116 (21): 994.

https://doi.org/10.1182/blood.V116.21.994.994

Published: 2010

Journal Articles

The Effect of Bortezomib On Bone Metabolism of Patients with Multiple Myeloma: a Korean Multicenter Prospective Study.

Chang-Ki Min, MD, Seok Jin Kim, MD, Je-Jung Lee, MD, Cheolwon Suh, MD, Jin Seok Kim, MD, Sung-Soo Yoon, MD, Byung Soo Kim, MD, Hye Jin Kang, MD, Young Jin Choi, MD, Cheol Soo Kim, MD, Yang Soo Kim, MD, Jae-Yong Kwak, MD, Yoo Jin Kim, MD, Young Don Joo, MD, Yeung-Chul Mun, MD, Deog Yeon Jo, MD, Joon Seong Park, MD, Chi-Young Park, MD, Sung Hyun Kim, MD

Blood (2009) 114 (22): 4871.

https://doi.org/10.1182/blood.V114.22.4871.4871

Published: 2009

Journal Articles

Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?

Youngil Koh, Soo-Mee Bang, MD, PhD, Jae Hoon Lee, Hwi-Joong Yoon, Young-Rok Do, PhD, Hun-Mo Ryoo, Nari Lee, Seok Jin Kim, MD, PhD, Sung-Soo Yoon, MD, PhD, Jong-Ho Won, MD, PhD, Yeung-Chul Mun, MD, PhD, Moon-Hee Lee, Jong-Youl Jin, MD, PhD, Hyo-Jung Kim, HyeonSeok Eom, MD, PhD, Min Kyoung Kim, MD, Hyun Chun Shin, Korean Multiple Myeloma Working Party

Blood (2008) 112 (11): 5146.

https://doi.org/10.1182/blood.V112.11.5146.5146

Published: 2008

Journal Articles

Up Regulation of transendothelial migration on Hematopoietic Progenitor Cells (HPC) and neutrophils by Leukotreine B 4 (LTB4) via elevated Endothelial Permeability

Yeung-Chul Mun, MD, PhD, Soo A. Oh, Moon Young Choi, Jee-Young Ahn, Kyoung-Eun Lee, Eun-Sun Yoo, Chu-Myong Seong

Blood (2008) 112 (11): 4783.

https://doi.org/10.1182/blood.V112.11.4783.4783

Published: 2008

Journal Articles

Outgrowing Endothelial Cells That Are Derived from Human Umbilical Cord Blood Improve Neovascularization in Hind-Limb Ischemia.

Eun-Sun Yoo, M.D., Ph.D., KiHwan Kwon, M.D., Ph.D., Jee-Young Ahn, M.S., Soo-Ah Oh, M.S., Hye-Jung Chang, M.D., Moon-Young Choi, M.D., Yeung-Chul Mun, MD, PhD, Kyoung-Eun Lee, M.D., Ph.D., Chu-Myong Seong, M.D.

Blood (2007) 110 (11): 3697.

https://doi.org/10.1182/blood.V110.11.3697.3697

Published: 2007

NARROW

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Long-Term Rivaroxaban for the Treatment of Acute Venous Thromboembolism in Patients with Active Cancer in a Prospective Multicenter Trial: KVTE13-01

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

Bleeding Complications in CAT Patients Treated with LMWH or DOACs

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Predictors of General Discomfort, Limitations in Activities of Daily Living, and Intention of a Second Donation in Unrelated Hematopoietic Stem Cell Donation

VEGFA and VEGFR2 Genetic Polymorphisms and Survival In Patients with Diffuse Large B Cell Lymphoma

The Effect of Bortezomib On Bone Metabolism of Patients with Multiple Myeloma: a Korean Multicenter Prospective Study.

Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?

Up Regulation of transendothelial migration on Hematopoietic Progenitor Cells (HPC) and neutrophils by Leukotreine B 4 (LTB4) via elevated Endothelial Permeability

Outgrowing Endothelial Cells That Are Derived from Human Umbilical Cord Blood Improve Neovascularization in Hind-Limb Ischemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only